ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2026
Complications of deep brain stimulation for drug-resistant epilepsy: an analysis from the MAUDE database.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeep brain stimulation (DBS) is an increasingly promising approach for patients with drug-resistant epilepsy (DRE). However, there are limited studies characterizing patient complications from DBS placement. MATERIALS AND
methodsUsing reports from the Manufacturer and User Facility Device Experience (MAUDE) database from January 2018 through March 2024, we systematically analyzed available data on patient complications/complaints, management strategies, and clinical outcomes. Only data from DBS implantations specifically to treat DRE were collected and analyzed.
resultsA total of 151 reports involving DBS treatment of DRE were analyzed. The most common DBS complications were device-related problems (DRPs, 95/151 [62.9%]) and patient complaints (PCs, 66/151 [43.7%]). The percentages exceed 100% because the categories overlap; some cases may fall into both categories, indicating that items in one category can also be included in another. The most prevalent DBS device-related complications included impedance issues (34/95 DRPs, 35.8%), device failure (32/95 DRPs, 33.7%), inadequate simulation (14/95 DRPs, 14.7%), and lead breaks (13/95 DRPs, 13.7%). The most prevalent patient complaints were worsening of seizure activity (20/66 PCs, 30.3%), psychiatric changes (9/66 PCs, 13.6%), and neurocognitive behavioral changes (8/66, 12.1%). Of the 151 reports, surgical intervention occurred for 20 (13.2%) patients; device failure had a surgical intervention rate of 9/32 (28%) while impedance issues had a rate of 7/34 (21%). Infections resulted in resolved outcomes in 6/13 (46.2%) of reports, most commonly treated with device removal (9/13, 69.2%).
conclusionsThe MAUDE database helps to more clearly define the risks and complications arising from DBS implantation to treat DRE. These results will help in assessing the risks, treatment alternatives, and outcomes associated with DBS device therapy for DRE. This will facilitate enhancements in the effectiveness of the device, better management of complications, and provide more comprehensive information to ensure patients can give informed consent.
Indexed as
Identifiers
42347948What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.